MCID: OPT009
MIFTS: 53

Optic Neuritis

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 72 49 36 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1210
ICD10 32 H46 H46.9
ICD9CM 34 377.3 377.30
MeSH 41 D009902
NCIt 46 C84950
KEGG 36 H01717
UMLS 69 C0029134

Summaries for Optic Neuritis

NIH Rare Diseases : 49 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated. Last updated: 1/11/2011

MalaCards based summary : Optic Neuritis is related to neuromyelitis optica and transverse myelitis, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Toxoplasmosis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include optic nerve which may cause a complete or partial loss of vision, eye and brain, and related phenotypes are behavior/neurological and hematopoietic system

Disease Ontology : 12 An optic nerve disease that results_in inflammation located in optic nerve which may cause a complete or partial loss of vision.

Wikipedia : 72 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 32.7 AQP4 HLA-DRB1 MBP MOG
2 transverse myelitis 32.5 AQP4 MBP TNF
3 optic nerve disease 31.9 AQP4 MOG MT-ND4
4 myelitis 30.6 AQP4 MBP MOG TNF
5 panencephalitis, subacute sclerosing 30.5 MBP MOG
6 encephalitis 30.5 AQP4 CCR5 MOG
7 acute disseminated encephalomyelitis 30.3 AQP4 HLA-DRB1 MBP MOG
8 rubella 30.2 HLA-DRB1 MOG TNF
9 allergic encephalomyelitis 30.1 MBP MOG PLP1
10 pediatric multiple sclerosis 30.1 HLA-DRB1 MOG
11 miller fisher syndrome 30.1 MAG TNF
12 relapsing-remitting multiple sclerosis 30.0 AQP4 MBP MOG TNF
13 cytomegalovirus retinitis 30.0 CCR5 TNF
14 internuclear ophthalmoplegia 29.9 AQP4 MBP MOG
15 neuroretinitis 29.9 AQP4 MOG
16 neuritis 29.8 AQP4 MAG MBP MOG MPZ MT-ND4
17 panuveitis 29.8 HLA-DRB1 TNF
18 psoriatic arthritis 29.4 HLA-DRB1 LTA TNF
19 chronic inflammatory demyelinating polyradiculoneuropathy 29.4 MBP MPZ
20 demyelinating disease 29.1 AQP4 MAG MBP MOG PLP1 TNF
21 polyneuropathy 29.1 MAG MBP MPZ
22 multiple sclerosis 27.3 AQP4 CCR5 CNTF HLA-DRB1 LTA MAG
23 isolated optic neuritis 12.2
24 chronic relapsing inflammatory optic neuropathy 11.7
25 retinitis 10.6
26 beryllium disease 10.4 HLA-DRB1 TNF
27 microscopic polyangiitis 10.4 HLA-DRB1 TNF
28 chronic beryllium disease 10.4 HLA-DRB1 TNF
29 autoimmune pancreatitis 10.4 HLA-DRB1 TNF
30 lichen sclerosus 10.4 HLA-DRB1 TNF
31 actinic prurigo 10.4 HLA-DRB1 TNF
32 acute hemorrhagic leukoencephalitis 10.4 AQP4 MBP
33 nontuberculous mycobacterial lung disease 10.4 HLA-DRB1 TNF
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
35 microscopic colitis 10.4 HLA-DRB1 TNF
36 central nervous system vasculitis 10.3 HLA-DRB1 TNF
37 rheumatoid vasculitis 10.3 HLA-DRB1 TNF
38 neuropathy 10.3
39 balo concentric sclerosis 10.3 AQP4 MBP MOG
40 alveolar echinococcosis 10.3 HLA-DRB1 TNF
41 orofacial granulomatosis 10.3 CCR5 TNF
42 ischemic optic neuropathy 10.3
43 cranial nerve disease 10.2 AQP4 MOG MT-ND4
44 traumatic brain injury 10.2 AQP4 MBP
45 hemorrhagic fever 10.2 HLA-DRB1 TNF
46 systemic lupus erythematosus 10.2
47 lupus erythematosus 10.2
48 spondylarthropathy 10.2 LTA TNF
49 transient hypogammaglobulinemia 10.2 LTA TNF
50 streptococcal toxic-shock syndrome 10.2 LTA TNF

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):


Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:


eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 MOG CCR5 MPZ CNTF PLP1 LTA
2 hematopoietic system MP:0005397 10.02 MOG CCR5 MPZ CNTF PLP1 LTA
3 homeostasis/metabolism MP:0005376 9.96 CCR5 MPZ CNTF PLP1 LTA SOD3
4 immune system MP:0005387 9.9 MPZ CNTF PLP1 LTA SOD3 MAG
5 nervous system MP:0003631 9.65 MOG CCR5 MPZ CNTF PLP1 LTA
6 vision/eye MP:0005391 9.17 MOG CCR5 PLP1 LTA MBP AQP4

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
4
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
5
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
6
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
7
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
10 Adrenocorticotropic Hormone Phase 4,Early Phase 1
11 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 beta-endorphin Phase 4,Early Phase 1
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Melanocyte-Stimulating Hormones Phase 4,Early Phase 1
22 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
23 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
24 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
27 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
28 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
29 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Analgesics Phase 4
34 Topoisomerase Inhibitors Phase 4
35 Antimetabolites Phase 4,Phase 3,Phase 2
36 Vitamin B Complex Phase 4,Phase 1
37 Anti-Infective Agents Phase 4,Phase 2,Phase 3
38 Antiviral Agents Phase 4,Phase 2,Phase 3
39 Interferon-beta Phase 4,Phase 2,Phase 3
40 interferons Phase 4,Phase 2,Phase 3
41 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3
42 Dermatologic Agents Phase 4,Phase 2
43 Anti-Bacterial Agents Phase 4,Phase 2
44 Antibiotics, Antitubercular Phase 4
45 Antitubercular Agents Phase 4
46 Folate Nutraceutical Phase 4,Phase 1
47 Vitamin B9 Nutraceutical Phase 4,Phase 1
48
Simvastatin Approved Phase 3 79902-63-9 54454
49
4-Aminopyridine Approved Phase 2, Phase 3 504-24-5 1727
50
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 96)

# Name Status NCT ID Phase Drugs
1 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
4 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
5 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
6 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
7 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
8 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
9 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
10 A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
11 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
12 Simvastatin Treatment of Patients With Acute Optic Neuritis Unknown status NCT00261326 Phase 3 simvastatin;placebo
13 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
14 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
15 Optic Neuritis Recovery After Oral or IV Corticosteroids Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
16 Ampyra for Optic Neuritis in MS Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
17 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
18 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
19 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
20 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3 Erythropoietin
21 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
22 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
23 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
24 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
25 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT01962571 Phase 3 Erythropoietin alfa;Placebo
26 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3 MD1003 100mg capsule
27 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
28 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
29 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
30 MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
31 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
32 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis Withdrawn NCT01337427 Phase 3 BIIB017
33 Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
34 Amiloride Clinical Trial In Optic Neuritis Unknown status NCT01802489 Phase 2 Amiloride;Placebo
35 Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
36 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
37 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
38 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
39 BIIB033 In Acute Optic Neuritis (AON) Completed NCT01721161 Phase 2 Placebo
40 Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis Completed NCT00355095 Phase 2 Erythropoietin
41 Neuroprotection With Phenytoin in Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
42 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
43 Long-Term Assessment of Remyelinating Therapy Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
44 Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Completed NCT00395200 Phase 1, Phase 2
45 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
46 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
47 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
48 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
49 High-Dose Vitamin D Induction in Optic Neuritis Recruiting NCT03302585 Phase 2 Vitamin D3;Placebo/Standard of Care Vitamin D3
50 Gypenosides Treatment for Optic Neuritis Recruiting NCT02976766 Phase 2 Gypenosides;Placebo

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

18
Optic Nerve Which May Cause A Complete Or Partial Loss Of Vision

MalaCards organs/tissues related to Optic Neuritis:

38
Eye, Brain, T Cells, Testes, Bone, Pituitary, Breast

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 788)
# Title Authors Year
1
High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. ( 29249380 )
2018
2
Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. ( 29363529 )
2018
3
Guillain-BarrAc syndrome and optic neuritis after Mycoplasma pneumoniae infection. ( 29429558 )
2018
4
Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. ( 29297053 )
2018
5
Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases. ( 29283135 )
2018
6
Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29259999 )
2018
7
Erratum: Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29417957 )
2018
8
Early Nodal and Paranodal Disruption in Autoimmune Optic Neuritis. ( 29444299 )
2018
9
Advanced diffusion-weighted imaging in patients with optic neuritis deficit - value of reduced field of view DWI and readout-segmented DWI. ( 29417865 )
2018
10
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. ( 29445944 )
2018
11
Valuable Insights Into Visual Neuroplasticity After Optic Neuritis. ( 29297048 )
2018
12
Paediatric ADEM followed by optic neuritis: disease course, treatment response and outcome. ( 29443442 )
2018
13
Incidence and Causes of Overdiagnosis of Optic Neuritis. ( 29222573 )
2018
14
Anti-NMDA-receptor optic neuritis in a patient with a history of encephalitis. ( 29217046 )
2017
15
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
16
Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis. ( 28820014 )
2017
17
Time is vision in recurrent optic neuritis. ( 28823952 )
2017
18
Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis. ( 28887838 )
2017
19
The Renin-Angiotensin System Regulates Neurodegeneration in a Mouse Model of Optic Neuritis. ( 28919108 )
2017
20
Concurrent intramedullary spinal cord and multiple intracranial tuberculomas with tuberculous optic neuritis: A rare case report. ( 28941861 )
2017
21
Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. ( 27862614 )
2017
22
Recurrent isolated optic neuritis: A study on 22 patients. ( 29114368 )
2017
23
Therapeutic benefit of environmental enrichment on optic neuritis. ( 29233635 )
2017
24
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. ( 28903961 )
2017
25
Clinical Profile and Outcomes of Optic Neuritis in an HIV Prevalent Urban Community in South Africa. ( 29279653 )
2017
26
Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. ( 28914353 )
2017
27
Should Oral Corticosteroids Be Used to Treat Demyelinating Optic Neuritis? ( 28857910 )
2017
28
Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. ( 28879451 )
2017
29
Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis. ( 28860702 )
2017
30
Optic neuritis in dogs: 96 cases (1983-2016). ( 29251394 )
2017
31
Prevalence and Incidence of Optic Neuritis in Patients with Different Types of Uveitis. ( 28895765 )
2017
32
Pediatric Optic Neuritis. ( 28941527 )
2017
33
Neuroprotection and visual function after optic neuritis. ( 27941524 )
2017
34
Thickness of macular inner retinal layers and peripapillary retinal nerve fibre layer in neuromyelitis optica spectrum optic neuritis and isolated optic neuritis with one episode. ( 27775238 )
2017
35
Cortical blindness and not optic neuritis as a cause of vision loss in a SjAPgren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report. ( 28834867 )
2017
36
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. ( 27844165 )
2017
37
Optic neuritis in a patient with celiac disease. ( 28803640 )
2017
38
Clinical usefulness of prognostic biomarkers in optic neuritis. ( 29272057 )
2017
39
Isolated optic neuritis associated with Mycoplasma pneumoniae infection: report of two cases and literature review. ( 28321515 )
2017
40
A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. ( 29055448 )
2017
41
Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect. ( 28754639 )
2017
42
Magnetic resonance imaging findings at the first episode of acute optic neuritis. ( 29291481 )
2017
43
Optic Neuritis in the Older Chinese Population: A 5-Year Follow-Up Study. ( 29375910 )
2017
44
Isolated palatal weakness without optic neuritis as the presenting manifestation of multiple sclerosis and its diagnostic dilemma with acute disseminated encephalomyelitis in a young boy. ( 28469990 )
2017
45
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. ( 28850630 )
2017
46
Acute Zonal Occult Outer Retinopathy Associated With Retrobulbar Optic Neuritis. ( 28252457 )
2017
47
Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. ( 28125740 )
2017
48
Differences in pupillary light reflex between optic neuritis and ischemic optic neuropathy. ( 29049405 )
2017
49
Pediatric Optic Neuritis: What Is New. ( 28806345 )
2017
50
UNILATERAL OPTIC NEURITIS AND CENTRAL RETINAL VASCULITIS DUE TO OCULAR SYPHILIS. ( 28816862 )
2017

Variations for Optic Neuritis

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.82 CCR5 HLA-DRB1 TNF
2 11.65 AQP4 PLP1 TNF
3 11.49 HLA-DRB1 MAG MPZ
4 11.34 AQP4 MAG MBP TNF
5 10.8 HLA-DRB1 TNF
6 9.7 MAG MBP PLP1

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 AQP4 CCR5 HLA-DRB1 LTA MAG MBP
2 external side of plasma membrane GO:0009897 9.46 AQP4 CCR5 HLA-DRB1 TNF
3 compact myelin GO:0043218 8.96 MAG MBP
4 myelin sheath GO:0043209 8.92 MAG MBP MPZ PLP1

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.65 CCR5 HLA-DRB1 LTA MBP TNF
2 response to hypoxia GO:0001666 9.63 LTA MT-ND4 SOD3
3 negative regulation of growth of symbiont in host GO:0044130 9.43 LTA TNF
4 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.4 MAG MPZ
5 central nervous system myelination GO:0022010 9.37 MAG PLP1
6 myelination GO:0042552 9.33 MBP MPZ PLP1
7 axon ensheathment GO:0008366 9.32 MBP PLP1
8 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 LTA TNF
9 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 LTA TNF

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.16 LTA TNF
2 structural constituent of myelin sheath GO:0019911 8.96 MBP PLP1
3 virus receptor activity GO:0001618 8.8 CCR5 HLA-DRB1 MOG

Sources for Optic Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....